Oncimmune Holdings PLC Correction to interim results (9046C)
15 Juin 2023 - 6:16PM
UK Regulatory
TIDMONC
RNS Number : 9046C
Oncimmune Holdings PLC
15 June 2023
15 June 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company" or the "Group")
Correction to unaudited interim results for the 12 months to 31
May 2022
Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
today announces that a one-off error has been identified in the
unaudited interim results for the 12 months to 31 May 2022, which
were announced on 21 September 2022.
The financial results of one of the Company's subsidiaries were
incorrectly consolidated into the overall financial results of the
Group, resulting in an overstatement of GBP0.7 million for both
revenue and cost of sales. It is important to note that this error
had no effect on gross profit, or the operating loss, previously
reported, nor has it had any effect on the reported cash
position.
Furthermore, this one-off error has had no effect on the audited
final results for the 15-month period to 31 August 2022, which were
announced on 28 February 2023. The unaudited interim results for
the six months ended 28 February 2023, as announced on 31 May 2023,
were similarly unaffected save for the comparative data for the 12
months to May 2022 in the consolidated income statement.
The Company intends to publish corrected unaudited interim
results for the 12 months to 31 May 2022 in due course.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leader in autoantibody profiling to the
pharmaceutical and biotechnology industry, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and
infectious diseases. The ImmunoINSIGHTS service business leverages
Oncimmune's technology platform and methodologies across multiple
diseases, to offer life-science organizations actionable insights
for therapies across the development and product lifecycle. Our
core immune-profiling technology is underpinned by our library of
over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the
Company's discovery research centre in Dortmund, Germany. The
business platform enables life science organizations to optimize
drug development and delivery, leading to more effectively targeted
and safer treatments for patients.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUUGQUPWGQA
(END) Dow Jones Newswires
June 15, 2023 12:16 ET (16:16 GMT)
Oncimmune (LSE:ONC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Oncimmune (LSE:ONC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024